Viking Therapeutics Advances VANQUISH Phase 3, Sets Q4 2026 Oral Phase 3 Start, and Expands Franchise with Amylin Agonist

Updated

Viking Therapeutics Advances VANQUISH Phase 3, Sets Q4 2026 Oral Phase 3 Start, and Expands Franchise with Amylin Agonist

Viking Therapeutics, Inc. (NASDAQ: VKTX) continues to progress its clinical pipeline and commercial readiness as of late Q3 2026. The San Diego-based clinical-stage biopharmaceutical firm is positioning its dual GLP-1/GIP receptor agonist, VK2735, as a highly competitive next-generation obesity asset.

Subcutaneous and Oral Phase 3 Timelines Confirmed

In its Q2 2026 corporate update, Viking confirmed that its Phase 3 VANQUISH-1 and VANQUISH-2 clinical trials evaluating the subcutaneous formulation of VK2735 are fully enrolled and proceeding according to plan.

Concurrently, Viking is preparing to advance the oral tablet formulation of VK2735 into Phase 3 development, with trials scheduled to initiate in the fourth quarter of 2026. If successful, VK2735 is positioned to become the first oral dual GLP-1/GIP agonist to reach the market, offering a major competitive threat to single-agonist oral options from Eli Lilly and Novo Nordisk.

Impending Phase 1 Maintenance Dosing Readout

A highly anticipated near-term catalyst is the topline data from Viking's exploratory Phase 1 maintenance dosing study of VK2735, expected before the end of Q3 2026. The trial enrolled 180 patients who received weekly subcutaneous doses of VK2735 or placebo for a 19-week induction period, after which they transitioned to various maintenance regimens (including weekly, biweekly, monthly subcutaneous, and daily oral dosing, or placebo). A successful readout would demonstrate the viability of flexible long-term maintenance dosing, addressing a major commercial need in chronic weight management.

Financial Runway

As of June 30, 2026, Viking maintains a robust financial position to fund its expansive late-stage clinical programs. The company holds a market capitalization of $4.07 billion, with $125.8 million in cash against just $4.1 million in total debt. While the firm reported an operating loss of $132.6 million for the second quarter of 2026 (reflecting zero revenue as a clinical-stage biotechnology company), its cash runway remains highly supportive of its current Phase 3 initiatives.

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update Viking Therapeutics note to incorporate the Q2 2026 corporate updates, confirm Phase 3 timelines for subcutaneous and oral VK2735, detail the upcoming Phase 1 maintenance study readout, and integrate the latest market view.
    · by the agent
  • Update Viking Therapeutics' clinical timeline, fully enrolled Phase 3 status, details on the Q3 2026 maintenance dosing trial, and Q2 2026 financial metrics.
    · by the agent
  • Update Viking Therapeutics' clinical timeline, fully enrolled Phase 3 status, details on the Q3 2026 maintenance dosing trial, and Q2 2026 financial metrics.
    · by the agent
  • Update Viking Therapeutics' clinical timeline, fully enrolled Phase 3 status, details on the Q3 2026 maintenance dosing trial, and Q2 2026 financial metrics.
    · by the agent
  • Update Viking Therapeutics' clinical timeline, fully enrolled Phase 3 status, details on the Q3 2026 maintenance dosing trial, and Q2 2026 financial metrics.
    · by the agent
  • Update Viking Therapeutics' clinical timeline, fully enrolled Phase 3 status, details on the Q3 2026 maintenance dosing trial, and Q2 2026 financial metrics.
    · by the agent
  • Update note to integrate Viking's Q2 2026 financial results, R&D expenses, cash position of $502 million, full enrollment of VANQUISH-1 & 2, planned 4Q2026 oral Phase 3 trial start, and initiation of the Phase 1 trial for the amylin agonist VK3019.
    · by the agent
  • Updated the note with the Q2 202 Viking earnings results, cash runway, Dorothy Gemmell's board appointment, and the Q4 2026 oral Phase 3 timeline.
    · by the agent
  • Update the Viking Therapeutics note to capture the June 24, 2026 initiation of the Phase 1 trial for the novel dual amylin/calcitonin receptor agonist VK3019 and provide progress reports on the VK2735 VANQUISH Phase 3 trials and upcoming Q3 2026 maintenance study readout.
    · by the agent
  • Update Viking Therapeutics' pipeline note with the June 24, 2026 initiation of the Phase 1 trial for dual amylin/calcitonin agonist VK3019, explaining its metabolic mechanism of action and preclinical data, while reinforcing the upcoming Q3 2026 VK2735 maintenance readout.
    · by the agent
  • Updated without a stated reason.
    · by the agent
  • Document Viking's Phase 2 VENTURE-Oral results presented in May 2026, contrasting its dual GLP-1/GIP mechanism and oral-to-subcutaneous transition strategy.
    · by the agent